Bayer HealthCare
Pharma
-
Thursday - November 13, 2008
No equal access to Multiple Sclerosis treatment and care in Europe
New findings presented by the European Multiple Sclerosis Platform at the European Parliament in Brussels / Bayer Schering Pharma presents new book for caregivers “Together we’ll make it”
-
Monday - November 10, 2008
Secondary Prevention in Acute Coronary Syndrome (ACS):
Bayer’s Xarelto® Shows Encouraging Results in Patients with Acute Coronary Syndrome
Phase II Data Presented as Late-Breaker at American Heart Association Meeting / Phase III Study to be Initiated in December 2008
-
Wednesday - October 29, 2008
Bayer AG News Conference Call and Report for the Third Quarter of 2008
-
Wednesday - October 29, 2008
Interim report for the third quarter of 2008:
Bayer optimistic about future business trend
Sales rise by 2.0 percent to EUR 7,948 million (Q3 2007: EUR 7,793 million) / HealthCare and CropScience improve earning power / MaterialScience earnings significantly lower / Group EBITDA before special items down 4.2 percent to EUR 1,493 million (Q3 2007: EUR 1,559 million) / Group EBIT before special items down 6.5 percent to EUR 891 million (Q3 2007: EUR 953 million) / Full-year guidance for 2008 confirmed / Continued earnings growth predicted for 2009
-
Thursday - October 16, 2008
First estradiol-based oral contraceptive Qlaira® cleared for market launch in Europe
A new oral contraceptive providing the same estrogen produced by the female body
-
Wednesday - October 15, 2008
“7th International Dialogue on Population and Sustainable Development” in Berlin:
Promoting health care and human rights in developing countries
Results will help to achieve the Millennium Development Goals and be incorporated into the 2009 International Conference on Population and Development / Bayer Schering Pharma supports family planning programs around the world
-
Monday - October 13, 2008
European Journalists’ Prize 2008 announced
Association of German Medical Journalists (VDMJ) and Bayer HealthCare honor good medical reporting
-
Monday - October 6, 2008
Novel approach for the treatment of pulmonary hypertension
Bayer Reports Progress in Clinical Program for Riociguat
Positive Phase II Findings Reported at European Respiratory Society Meeting / Phase III Studies to Begin in 2008
-
Wednesday - October 1, 2008
Venous Blood Clot Prevention after Elective Hip or Knee Replacement Surgery:
Bayer’s Novel Anticoagulant Xarelto® now also Approved in the EU
Bayer will start marketing the new oral, once-daily anticoagulant very soon / First-in-class product to demonstrate superior efficacy to current standard of care
-
Tuesday - September 30, 2008
Pre-Clinical Cancer Research:
Bayer starts new research cooperation in Asia
Research collaboration with National University of Singapore signed / Further collaborations planned / Overall investment volume of 10 million Euro
-
Sunday - September 28, 2008
Final Phase 2 Results Presented at Retina Society Meeting
VEGF Trap-Eye: New Data Confirm Successes in the Treatment of Age-related Macular Degeneration
Statistically significant reduction in the size of the affected area of the retina demonstrated
-
Thursday - September 25, 2008
Bayer Schering Pharma AG
Squeeze-out entered in the Commercial Register
Squeeze-out of minority stockholders takes effect / Cash compensation of EUR 98.98 per share will be paid
-
Saturday - September 20, 2008
Results of Landmark BENEFIT trial presented at WCTRIMS:
Five year data confirm that early treatment with Betaferon® at first sign of disease can delay progression to MS
BENEFIT is first and only prospectively planned study to show long lasting benefit of early treatment
-
Tuesday - September 16, 2008
Advances in Renal Cancer Journalists’ Award Europe announced
Bayer HealthCare and Association of German Medical Journalists (VDMJ) honor good medical reporting about Renal Cancer - Award is endowed with EUR 7,500
-
Tuesday - September 16, 2008
Bayer HealthCare acquires German DIREVO Biotech AG
A recognized leader in protein engineering / Expanding technological know-how in biologicals / Strengthening Bayer HealthCare’s commitment to develop innovative biologicals
-
Tuesday - September 16, 2008
Venous Blood Clot Prevention after Elective Total Knee and Hip Replacement Surgery:
Bayer’s Xarelto® Approved in Canada
First approval for Bayer’s new oral, once-daily anticoagulant / Marketing to start immediately / First-in-class product to demonstrate superior efficacy to standard of care / Most studied oral, direct Factor Xa inhibitor in the world today
-
Monday - September 15, 2008
Bayer offers thinnest needle for its multiple sclerosis treatment Betaferon® in the U.S.
-
Wednesday - September 10, 2008
Molecular Imaging:
Bayer Intensifies Research in Early Diagnosis of Alzheimer’s Disease
Licensing agreement with Nagasaki University signed
-
Monday - September 8, 2008
New low-dose oral contraceptive YAZ® launched in Europe
24/4 dosing regimen has shown to reduce hormone fluctuations
-
Tuesday - September 2, 2008
Bayer Submits Recombinant Human Thrombin for European Approval
Recothrom® would be the first recombinant human thrombin for use as a topical aid to surgical hemostasis in Europe
Search
Links
Publications
Stockholders' Newsletter
Annual Report 2007
Sustainable Development Report 2007
research – The Bayer Scientific Magazine
Publications Overview
Newsletter
Events
Download Center - Selection